Cancer Treatment:
National Cancer Institute's Role in Encouraging the Use of Breakthroughs
PEMD-89-4BR: Published: Oct 20, 1988. Publicly Released: Nov 21, 1988.
Additional Materials:
- Full Report:
Contact:
(202) 275-3092
contact@gao.gov
Office of Public Affairs
(202) 512-4800
youngc1@gao.gov
In response to a congressional request, GAO examined the role that the National Cancer Institute (NCI) plays in promoting physicians' utilization of breakthroughs in cancer therapies.
GAO found that: (1) problems existed at many points in the process that breakthrough treatments take to reach cancer patients; (2) NCI had difficulties in coordinating its position on recommended treatments, so that physicians sometimes received many or conflicting responses to requests for advice on treatments; (3) NCI efforts at disseminating information on new treatments to physicians had limited success; and (4) many cancer patients did not receive what NCI considered state-of-the-art treatment because physicians often did not adopt treatments even after they received information concerning them.
Matter for Congressional Consideration
Status: Closed - Not Implemented
Comments: No congressional action is anticipated.
Matter: Congressional committees that are concerned about efforts to promote the adoption of cancer treatment advances may want to consider steps to specifically mandate federal action. This could include directing NCI, or some other office created for this purpose, to undertake efforts to clearly identify and promote the use of cancer therapies that have been sufficiently proven to warrant being classified as recommended treatments.
Explore the full database of GAO's Open Recommendations
»
Mar 1, 2021
-
Medicare Part B:
Payments and Use for Selected New, High-Cost DrugsGAO-21-252: Published: Mar 1, 2021. Publicly Released: Mar 1, 2021.
Feb 24, 2021
-
Covid-19:
Key Insights from GAO's Oversight of the Federal Public Health ResponseGAO-21-396T: Published: Feb 24, 2021. Publicly Released: Feb 24, 2021.
Feb 17, 2021
Feb 11, 2021
-
Operation Warp Speed:
Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing ChallengesGAO-21-319: Published: Feb 11, 2021. Publicly Released: Feb 11, 2021.
Feb 5, 2021
-
DOD Health Care:
DOD Should Monitor Implementation of Its Clinical Practice GuidelinesGAO-21-237: Published: Feb 5, 2021. Publicly Released: Feb 5, 2021. -
Medicaid:
CMS Needs to Implement Risk-Based Oversight of Puerto Rico's Procurement ProcessGAO-21-229: Published: Feb 5, 2021. Publicly Released: Feb 5, 2021. -
VA Health Care:
Community Living Centers Were Commonly Cited for Infection Control Deficiencies Prior to the COVID-19 PandemicGAO-21-195R: Published: Jan 6, 2021. Publicly Released: Feb 5, 2021.
Jan 28, 2021
-
COVID-19:
Critical Vaccine Distribution, Supply Chain, Program Integrity, and Other Challenges Require Focused Federal AttentionGAO-21-265: Published: Jan 28, 2021. Publicly Released: Jan 28, 2021.
Jan 21, 2021
-
Rural Hospital Closures:
Affected Residents Had Reduced Access to Health Care ServicesGAO-21-93: Published: Dec 22, 2020. Publicly Released: Jan 21, 2021. -
Health Care Funding:
Federal Obligations to and Funds Received by Certain Organizations Involved in Health-Related Services, 2016 through 2018GAO-21-188R: Published: Dec 21, 2020. Publicly Released: Jan 21, 2021.
Looking for more? Browse all our products here